Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

270
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
270
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

271
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
271
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

338
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
338
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

402
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
402
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

152
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
152

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Insights into Pathogenesis of Chronic Spontaneous Urticaria.

The British journal of dermatology·2026
Same author

Biomarkers in atopic dermatitis: Current evidence and unmet needs.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Treatment Approaches for Omalizumab-Refractory Chronic Spontaneous Urticaria.

Journal of inflammation research·2026
Same author

Global Real-World Validation of First-Day Urticaria Activity Score (UAS1).

The journal of allergy and clinical immunology. In practice·2026
Same author

Clinical phenotypes and molecular endotypes of chronic urticaria: Linking clinical expression to underlying immune mechanisms.

Asia Pacific allergy·2026
Same author

The Overall Burden of Chronic Spontaneous Urticaria - The Current Landscape.

The British journal of dermatology·2026

Related Experiment Video

Updated: Jun 22, 2025

Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

8.1K

Emerging Therapeutics in Chronic Urticaria.

Melba Muñoz1, Emek Kocatürk2, Marcus Maurer1

  • 1Institute of Allergology, Charité - Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health; Department of Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Hindenburgdamm 27, Berlin 12203, Germany.

Immunology and Allergy Clinics of North America
|June 27, 2024
PubMed
Summary

New treatments for chronic urticaria (CU), a chronic skin condition, are in development. These therapies target underlying causes to improve efficacy for patients with limited options.

Keywords:
BTK inhibitorsBarzolvolimabChronic inducible urticariaChronic spontaneous urticariaChronic urticariaDupilumabNovel treatment

More Related Videos

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

439
An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation
08:25

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation

Published on: April 27, 2021

2.4K

Related Experiment Videos

Last Updated: Jun 22, 2025

Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

8.1K
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

439
An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation
08:25

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation

Published on: April 27, 2021

2.4K

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Chronic urticaria (CU) is a prevalent mast cell-mediated skin disease.
  • CU significantly impacts quality of life and is linked to comorbidities.
  • Current treatments often have limited efficacy due to diverse pathophysiology.

Purpose of the Study:

  • To review emerging therapeutics for chronic urticaria.
  • To discuss novel treatments targeting mast cells and immune pathways.
  • To evaluate the potential future role of these advanced therapies in CU management.

Main Methods:

  • Focus on promising therapeutics in advanced development for CU.
  • Analysis of small molecules and monoclonal antibodies.
  • Discussion of targets including mast cells, receptors, signaling pathways, and other immune cells.

Main Results:

  • Several novel therapeutic agents are in advanced stages of development for CU.
  • These agents employ targeted mechanisms to address underlying CU pathophysiology.
  • Potential for improved efficacy and broader treatment options compared to existing therapies.

Conclusions:

  • Emerging therapeutics show promise for more effective CU management.
  • Targeted therapies offer a disease-modifying approach for CU.
  • Future CU treatment landscape will likely include these novel agents.